𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site

✍ Scribed by Alberto Muñoz; José Ramón Barceló; Guillermo López-Vivanco

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
67 KB
Volume
101
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

tional RCC and extensively cystic Bosniak Grade 2 or 3 disease, which may be difficult to diagnose reliably using either fine-needle or core-needle biopsy. Correlation of the results presented by Volpe et al. with the additional findings discussed in the current correspondence may be useful.

📜 SIMILAR VOLUMES

Gemcitabine and docetaxel as front-line
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site
✍ Damien Pouessel; Stéphane Culine; Catherine Becht; Marc Ychou; Gilles Romieu; Mi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

## Abstract ## BACKGROUND The current study was performed to evaluate the efficacy and toxicity of a noncisplatin‐based chemotherapy regimen combining gemcitabine and docetaxel as front‐line chemotherapy for patients with carcinoma of an unknown primary site. ## METHODS Patients were to receive

Phase II trial of carboplatin, gemcitabi
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site
✍ Bryan J. Schneider; Basil El-Rayes; Jeffery H. Muler; Philip A. Philip; Gregory 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND. The purposes of this study were to evaluate efficacy and toxicity of the combination of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site (CUP). ## METHODS. Patients with CUP received carboplatin AUC 5 mg/mL a minute intraven

Docetaxel/cisplatin as first-line chemot
Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma : A Phase II trial
✍ Martina Baur; Heinz-Roland Kienzer; Johannes Schweiger; Maria DeSantis; Erich Ge 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this Phase II study was to assess the clinical activity and toxicity of docetaxel (D) and cisplatin (P) in patients with locally advanced unresectable, metastatic, or recurrent squamous cell carcinoma of the head and neck (SCCHN). ## PATIENTS Of 34 pati